A Prospective Trial of Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide for Newly Diagnosed Glioblastoma Multiforme

Trial Profile

A Prospective Trial of Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide for Newly Diagnosed Glioblastoma Multiforme

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Oct 2017 Planned End Date changed from 1 Jan 2016 to 1 Jan 2018.
    • 05 Oct 2017 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2018.
    • 19 Nov 2015 Planned end date changed from 1 May 2015 to 1 Jan 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top